Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mucus in the upper respiratory tract is a complex, viscous secretion produced primarily by goblet cells and submucosal glands lining the airways. Its primary functions include trapping inhaled pathogens and particulates, protecting the airway epithelium from environmental insults, facilitating removal via mucociliary clearance, and contributing to immune defense. The major macromolecular components are gel-forming mucins (mainly MUC5AC and MUC5B). Changes in mucus quality, such as in hyperconcentration, dehydration, or overproduction, play a key role in several airway diseases, including cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, and asthma. Mucus itself is not a classical drug target; rather, therapies act on its physical properties or underlying regulation, not on “mucus” as a single molecule or receptor.
Disruption of mucin polymers to decrease viscosity - Hydration of mucus to enhance clearance - Restoration of ion transport/airway surface hydration (in CF)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucus (upper respiratory tract).